1,185companies with two captured documents
EVIDENCE DELTA
What changed between disclosures?
Compare extracted themes and source excerpts across a company’s two latest captured management documents.RUB
RUBICONRubicon Research Limited
15 changesPricing pressureNot surfaced now · risk
75/100→Not surfaced
PRIOR DOCUMENTThis broad- based growth has been driven by both market share gains in established products and the successful commercialisation of new product launches. Nuanced portfolio strategy reflected in sustained market economics US Generics Price Erosion by Therapy Area Rubicon’s Portfolio 8.0% 1.3% 21.8% -0.1% -5.2 Cardiovascular 11.2% Alimentary Tract and Metabolism Oncology Nervous System Industry Average Source: Frost &
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Margin pressureNot surfaced now · risk
80/100→Not surfaced
PRIOR DOCUMENTCAPEX should therefore follow demand and this approach allows us to tailor our investments better to our portfolio needs. We incur outsourced manufacturing cost and suffer gross margin pressure in the short term but we protect the trust our customers place in us to be a reliable supplier. When Pithampur comes online and ramps up through calendar year 2027, we should see some outsourced production moving back in-house
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Regulatory observationNot surfaced now · risk
77/100→Not surfaced
PRIOR DOCUMENTThis is a large site with capabilities in steroids, hormones, and high-potency oncology products — areas where we currently have no internal manufacturing. The US FDA recently inspected the facility from 29 June to 3 July 2026 and issued 2 procedural observations in Form 483. We are confident of a successful and timely inspection closure and expect commercial production to ramp up from Q1 CY27 as previously guided.
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Margin expansionEased · opportunity
71/100→30/100
PRIOR DOCUMENTOur approach centres on addressing unmet patient needs and securing early market entry. Specialty products provide higher margins due to their differentiated value. Extensive scientific and market research ensures that our products align with prescriber and payer criteria.
LATEST DOCUMENTAnd we have technically given away relatively lower margin business. And again, also look at also look at that if we are letting go of a relatively lower margin business, okay, in that choice making, we will do that only if we are securing a higher margin business. Prateek Shrivastava: Fair enough, fair enough, sir.
NEU
NEULANDLABNeuland Laboratories Limited
7 changesMargin pressureNewly surfaced · risk
Not surfaced→31/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTNeuland Laboratories Limited August 05, 2026 Page 15 of 15 Saharsh Davuluri: I think our margin profile is in a fairly comfortable space, Runjhun, and I think this is a reasonable margin to expect from this business, although there is a fairly divergent set of molecules. We see molecules which are having lower margins and higher margins. So eventually, it's the mix that will determine what the average profile is.
Management confidenceNewly surfaced · mixed
Not surfaced→62/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTMany of the investments we made over the last several years are beginning to create new opportunities across the business. While there will inevitably be periods of unevenness along the way, we remain confident in the direction of the company, the opportunities ahead of us and our ability to create long-term value. With that, we would be happy to take your questions.
Operating leverageNewly surfaced · opportunity
Not surfaced→65/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTTo summarize, the financials Q1 FY27 again was broadly in line with our expectations. The performance reflects disciplined execution, operating leverage and a favorable mix during the quarter. We continue to believe FY27 will be a year of growth for the company and remain focused on prudent financial management, operational excellence and creating long -term value for our stakeholders.
Margin expansionNewly surfaced · opportunity
Not surfaced→31/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTNeuland Laboratories Limited August 05, 2026 Page 15 of 15 Saharsh Davuluri: I think our margin profile is in a fairly comfortable space, Runjhun, and I think this is a reasonable margin to expect from this business, although there is a fairly divergent set of molecules. We see molecules which are having lower margins and higher margins. So eventually, it's the mix that will determine what the average profile is.
NAT
NATIONALUMNational Aluminium Company Limited
2 changesRaw material inflationNot surfaced now · risk
36/100→Not surfaced
PRIOR DOCUMENTAnd the second part is, I mean, we have seen now t hat the aluminum prices have come down. So going forward in Q2, do you foresee any raw material cost pressure, which will persist because we have seen in the earlier quarter, you have guided that there is some cost inflation on CP coke, coal tar pitch, and other raw materials. So, will it impact our margins going forward as the aluminum prices have cooled down?
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Export market updatesNot surfaced now · mixed
40/100→Not surfaced
PRIOR DOCUMENTSo supply restrictions, projections are there. There will be a deficit of around 0.88 million ton s of metal in the international market. If you see the production and consumption patterns, there is a deficit of around 0.88 million tons.
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
THY
THYROCAREThyrocare Technologies Limited
3 changesPricing pressureNewly surfaced · risk
Not surfaced→24/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTAnd so -- and as you know, as we add more tests in a per patient, the vial still remain the same, right? So to that extent, you will see some price erosion because we discount the incremental tests to encourage patients to do a more comprehensive panel versus the few initial tests that they thought about. So that's the effect you see when you look at it at vial level, but at the test level, it's more or less in line.
Management confidenceNewly surfaced · mixed
Not surfaced→71/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTOur focus is on building clinical trust through scientific rigor, consistent quality and industry-leading turnaround times. We are confident that the same disciplined investments and execution, the established Thyrocare leadership in preventative diagnostics will create a durable competitive advantage in specialty diagnostics. Our ambition is to build India's most trusted, accessible and scalable facility diagnostics
Margin expansionNewly surfaced · opportunity
Not surfaced→44/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTSo, I think once the franchise es will mature, the overall growth possibly will surpass the addition al growth itself. And that will bring in incremental operating Thyrocare Technologies Limited July 23, 2026 Page 19 of 19 leverage and hence, margin improvement. So, whether my thought process is off the tracks really.
CRA
CRAMCCanara Robeco Asset Management Company Limited
7 changesMargin pressureNot surfaced now · risk
56/100→Not surfaced
PRIOR DOCUMENTThese changes are expected to: Increase investor confidence. However, they may also lead to higher compliance costs and margin pressures for AMCs. Near-Term Headwinds Despite strong structural tailwinds, certain challenges persist: Equity inflow moderation during parts of the year with recovery coming in March 2026 with record inflows of `404.50 Billion.
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Demand slowdownNot surfaced now · risk
79/100→Not surfaced
PRIOR DOCUMENTPrimary market activity also remained healthy, with continued IPO momentum contributing to overall wealth creation. Annual Report 2025-26 28 Corporate Earnings and Growth Trend Corporate India’s earnings trajectory in FY 2025-26 reflected resilience amid a “wall of worry”—global tariffs, geopolitical tensions, and initial demand softness were offset by strong domestic engines (RBI easing, capex push, consumption reco
LATEST DOCUMENTThis signal was not surfaced in the latest captured document.
Margin expansionNewly surfaced · opportunity
Not surfaced→70/100
PRIOR DOCUMENTThis signal was not surfaced in the prior captured document.
LATEST DOCUMENTWe have been able to, of course, work out partnerships and in a way so that it remains beneficial for both the partners. And in combination of that, which is both in terms of working on our expenses and working with the partnerships to continue with our sharing with them, it has filtered in terms of margin improvement basis. So , is it right to attrib ute the additional cost total to NFOs in the last quarter and does
Regulatory updatesIntensified · mixed
46/100→75/100
PRIOR DOCUMENT1 2 Major Events & Drivers Market volatility remained elevated during the year, with equities navigating a “wall of worry” that included global trade disruptions, currency depreciation, and brief geopolitical tensions. However, the second half of the year witnessed improved sentiment, supported by monetary easing by the Reserve Bank of India, consumption-focused measures in the Union Budget 2025, tax and policy refor
LATEST DOCUMENTCosts are a certainty, revenues sometimes when markets are volatile may not be and we are very cognizant of it. But you're absolutely right, there is rising costs of compliance within the regulatory framework, but that's good for the investors and to make the ecosystem far more stable. But we are very well positioned, as you can see from our results as well.
Evidence Delta compares themes surfaced by TickerSutra’s document-analysis pipeline. A higher score means a theme was more prominent in the captured document; it is not a probability or investment rating. A topic not surfaced in one document may still remain relevant. Confirm the excerpts in both linked filings before drawing a conclusion.
Read the research methodology